JP2010524435A5 - - Google Patents

Download PDF

Info

Publication number
JP2010524435A5
JP2010524435A5 JP2010501433A JP2010501433A JP2010524435A5 JP 2010524435 A5 JP2010524435 A5 JP 2010524435A5 JP 2010501433 A JP2010501433 A JP 2010501433A JP 2010501433 A JP2010501433 A JP 2010501433A JP 2010524435 A5 JP2010524435 A5 JP 2010524435A5
Authority
JP
Japan
Prior art keywords
seq
cdr
set forth
region
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
JP2010501433A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010524435A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/002663 external-priority patent/WO2008119566A2/en
Publication of JP2010524435A publication Critical patent/JP2010524435A/ja
Publication of JP2010524435A5 publication Critical patent/JP2010524435A5/ja
Revoked legal-status Critical Current

Links

JP2010501433A 2007-04-03 2008-04-03 種間特異的二重特異性バインダー Revoked JP2010524435A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP07006988 2007-04-03
EP07006990 2007-04-03
US91366807P 2007-04-24 2007-04-24
EP07020646 2007-10-22
EP07020640 2007-10-22
EP07020641 2007-10-22
EP08004741 2008-03-13
PCT/EP2008/002663 WO2008119566A2 (en) 2007-04-03 2008-04-03 Cross-species-specific bispecific binders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013218769A Division JP6016747B2 (ja) 2007-04-03 2013-10-22 種間特異的二重特異性バインダー

Publications (2)

Publication Number Publication Date
JP2010524435A JP2010524435A (ja) 2010-07-22
JP2010524435A5 true JP2010524435A5 (enExample) 2011-05-19

Family

ID=42582614

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010501433A Revoked JP2010524435A (ja) 2007-04-03 2008-04-03 種間特異的二重特異性バインダー

Country Status (8)

Country Link
JP (1) JP2010524435A (enExample)
DK (1) DK2155788T3 (enExample)
ES (1) ES2390243T3 (enExample)
NZ (1) NZ580746A (enExample)
PT (1) PT2155788E (enExample)
RS (1) RS52492B (enExample)
RU (1) RU2535992C2 (enExample)
SI (1) SI2155788T1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4059964A1 (en) * 2007-04-03 2022-09-21 Amgen Research (Munich) GmbH Cross-species-specific binding domain
HRP20120759T1 (hr) * 2007-04-03 2012-10-31 Amgen Research (Munich) Gmbh Bispecifična veziva specifična između vrsta
EP3974453A3 (en) * 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
CN107903325B (zh) * 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
SI2714733T1 (sl) * 2011-05-21 2019-06-28 Macrogenics, Inc. CD3-vezavne molekule sposobne vezave na humani ali ne-humani CD3
HUE050156T2 (hu) 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
JP6738285B2 (ja) * 2014-05-28 2020-08-12 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒト及びカニクイザルcd3イプシロンに結合する抗体
US10669337B2 (en) * 2014-07-25 2020-06-02 Cytomx Therapeutics, Inc. Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
AR101400A1 (es) * 2014-07-31 2016-12-14 Amgen Res Munich Gmbh Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido
JP2018520642A (ja) * 2015-05-01 2018-08-02 ジェネンテック, インコーポレイテッド マスク抗cd3抗体及びその使用方法
AU2017233121B2 (en) 2016-03-15 2023-12-21 Itabmed (Hk) Limited Multispecific Fab fusion proteins and use thereof
MX2019005438A (es) 2016-11-15 2019-08-16 Genentech Inc Dosificacion para tratamiento con anticuerpos bispecificos anti-cd20 / anti-cd3.
US10426424B2 (en) 2017-11-21 2019-10-01 General Electric Company System and method for generating and performing imaging protocol simulations
CR20200391A (es) 2018-02-08 2020-10-19 Genentech Inc Moléculas biespecíficas de unión al antígeno y métodos de uso
JP7548587B2 (ja) 2018-09-07 2024-09-10 アイタブメッド (エイチケイ) リミテッド 二重特異性抗原結合タンパク質及びその使用
US20230067182A1 (en) * 2019-11-29 2023-03-02 Boe Technology Group Co., Ltd. Data Processing Device and Method, and Computer Readable Storage Medium
US11845799B2 (en) 2019-12-13 2023-12-19 Genentech, Inc. Anti-Ly6G6D antibodies and methods of use
JP2022087602A (ja) * 2020-12-01 2022-06-13 株式会社バイオピーク 組換え大腸菌による有用タンパク質の生産性を向上するための培養方法
WO2022241235A1 (en) 2021-05-14 2022-11-17 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
CN115932808B (zh) * 2022-11-04 2025-05-27 四川九洲电器集团有限责任公司 一种基于多特征融合的被动声纳智能探测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2179862C1 (ru) * 2000-12-26 2002-02-27 Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" Лекарственное средство для предотвращения отторжения трансплантата, моноклональное антитело к cd3-антигену т-лимфоцитов человека, гибридома и способ лечения больных, имеющих реакцию острого отторжения трансплантата после пересадки почки
BRPI0410338A (pt) * 2003-05-31 2006-05-30 Micromet Ag composição farmacêutica compreendendo um constructo de anticorpo biespecìfico para epcam, processo para sua produção, uso de um constructo biespecìfico, kit contendo o mesmo e método para a prevenção, tratamento ou alìvio de uma doença tumoral
US7235641B2 (en) * 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
AU2005250499B2 (en) * 2004-06-03 2011-12-08 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
EP1933868A2 (en) * 2005-09-12 2008-06-25 NovImmune SA Anti-cd3 antibody formulations
EP1940881B1 (en) * 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2010524435A5 (enExample)
HRP20120759T1 (hr) Bispecifična veziva specifična između vrsta
FI2155783T4 (fi) Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni
TWI769537B (zh) 標靶bcma的抗體、雙專一性抗體及其用途
JP2019501883A5 (enExample)
JP2020062036A5 (enExample)
JP2022061992A5 (enExample)
HRP20190932T1 (hr) Molekule protutijela koje se vežu na il-17a i il-17f
JP2017522892A5 (enExample)
JP2013528569A5 (enExample)
CN115003333A (zh) Pvrig结合蛋白及其医药用途
JP2013056885A5 (enExample)
JP2015504306A5 (enExample)
HRP20130883T4 (hr) Međuvrsno specifična cd3-epsilon-vežuća domena
JP2018526981A5 (enExample)
JP2014534242A5 (enExample)
JP2018521638A5 (enExample)
RU2019128134A (ru) Антитело против gprc5d и молекула, содержащая антитело
HRP20161216T1 (hr) Farmaceutski pripravci s otpornošću na topljivi cea
JP2016511277A5 (enExample)
JP2016512551A5 (enExample)
HRP20110187T1 (hr) Multispecifične deimunizirane tvari koje vežu cd3
RU2009136913A (ru) Биспецифические связывающие агенты с межвидовой специфичностью
JP2012504403A5 (enExample)
JP2016511750A5 (enExample)